These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 38490355

  • 1. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Tuberculosis Network European Trials group.
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [Abstract] [Full Text] [Related]

  • 2. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.
    Lange C, Kherabi Y, Guglielmetti L, Duarte R, Günther G, Tuberculosis Network European Trials group.
    Clin Microbiol Infect; 2024 Sep; 30(9):1207-1208. PubMed ID: 38901496
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies NA.
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
    Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, Dodd M, Foraida S, Gegia M, Li M, Mirzayev F, Morgan H, Motta I, Nguyen L, Schumacher S, Schlub T, Fox G.
    Clin Infect Dis; 2024 Mar 20; 78(3):730-741. PubMed ID: 37874021
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, SimpliciTB Consortium.
    Lancet Infect Dis; 2024 Sep 20; 24(9):1003-1014. PubMed ID: 38768617
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis.
    Li S-Y, Tyagi S, Soni H, Betoudji F, Converse PJ, Mdluli K, Upton AM, Fotouhi N, Barros-Aguirre D, Ballell L, Jimenez-Navarro E, Nuermberger EL.
    Antimicrob Agents Chemother; 2024 Apr 03; 68(4):e0156223. PubMed ID: 38376228
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid.
    Howell P, Upton C, Mvuna N, Olugbosi M.
    BMJ Case Rep; 2021 Dec 07; 14(12):. PubMed ID: 34876446
    [Abstract] [Full Text] [Related]

  • 17. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
    Li H, Salinger DH, Everitt D, Li M, Del Parigi A, Mendel C, Nedelman JR.
    Antimicrob Agents Chemother; 2019 Oct 07; 63(10):. PubMed ID: 31358590
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model.
    Bigelow KM, Tasneen R, Chang YS, Dooley KE, Nuermberger EL.
    Antimicrob Agents Chemother; 2020 Sep 21; 64(10):. PubMed ID: 32690647
    [Abstract] [Full Text] [Related]

  • 20. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
    Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D, Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A, Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel CM, Spigelman M, ZeNix Trial Team.
    N Engl J Med; 2022 Sep 01; 387(9):810-823. PubMed ID: 36053506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.